^
Association details:
| Biomarker: | KIAA1549-BRAF fusion + PTEN deletion |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + temsirolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
Excerpt:
The patient responded to combination targeted therapy that fortuitously targeted KIAA1549-BRAF and PTEN loss within a spindle cell neoplasm, as revealed by genomic profiling based on NGS. This is the first report of a tumor driven by a KIAA1549-BRAF fusion responding to sorafenib-based combination therapy.
DOI:
10.1186/1756-8722-7-8
Trial ID: